Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN7A | Q01118 | 4/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18556179 | 0.90 | SCN7A (0.44) | SCN7ASCN9ASCN5AMRGPRX4TRPM8 | |
| SCHEMBL18571134 | 0.90 | SCN7A (0.44) | SCN7ASCN9ASCN5AMRGPRX4TRPM8 | |
| SCHEMBL21800830 | 0.90 | SCN7A (0.44) | SCN7ASCN9ASCN5AMRGPRX4TRPM8 | |
| SCHEMBL23861668 | 0.90 | SCN7A (0.44) | SCN7ASCN9ASCN5AMRGPRX4TRPM8 | |
| SCHEMBL23861689 | 0.87 | SCN5A (0.45) | SCN7ASCN9ASCN5A | |
| SCHEMBL23861677 | 0.87 | SCN9A (0.46) | SCN9AMRGPRX4BRD4TRPM8 | |
| SCHEMBL18556031 | 0.86 | SCN7A (0.43) | SCN7ASCN9ASCN5ABRD4TRPM8 | |
| SCHEMBL18571143 | 0.86 | SCN7A (0.43) | SCN7ASCN9ASCN5ABRD4TRPM8 | |
| SCHEMBL18571084 | 0.84 | SCN7A (0.46) | SCN7ASCN9ASCN5AMRGPRX4PTGDR2 | |
| SCHEMBL17423083 | 0.80 | SCN7A (0.51) | SCN7ASCN9ASCN5AMRGPRX4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | RDX, C3AR1, LPXN | SCN7A 1281/4885SCN9A 1789/4885SCN5A 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.